Overview

A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)

Status:
Completed
Trial end date:
2021-04-09
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of FOY-305 in patients with SARS-CoV-2 infection (COVID-19) in a placebo-controlled, multicenter, double-blind, randomized, parallel-group comparative study.
Phase:
Phase 3
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Treatments:
Camostat